In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
Emerging pharma companies play an important role in new product development. Which companies are making strong plays based on recent high-value partnering deals? DCAT Value Chain Insights' Top 10 highlights the rising players.
Emerging pharma...
The biopharma industry, both biopharmaceutical/pharmaceutical companies and CDMOs/CMOS, has been a target of increased investment by private-equity (PE) firms. A recent analysis by Bain & Company examines financing trends and investments by PE...
CDMOs have met the operational challenges presented by the novel coronavirus (COVID-19) pandemic to date, but what is the near-term and long-term impact as biopharma companies re-access drug-development projects?
The novel coronavirus pandemic has...
Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh, discusses the importance of understanding crystallization processes to avoid unnecessary cost, risk and development delays.
Driven by growth in oncology drugs, high-potency manufacturing is an active area of investment by CDMOs/CMOs. Which CDMOs/CMOs are making investments? DCAT Value Chain Insights rounds up key recent expansions for drug substances and drug...
Immunotherapies represent a growing sector in the global oncology pharmaceutical market. Now led by Merck & Co.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), immunotherapies by Roche and AstraZeneca are joining the...
With Cambrex’s experience in combining two or more active pharmaceutical ingredients (APIs) into Fixed Dose Combination drugs (FDCs), we are the CDMO that’s expertly positioned to partner with you. Discover the benefits and challenges as we review...
As lockdown measures to COVID-19 are slowly being lifted globally, how are companies responding? A recent PwC survey of nearly 870 CFOs in 24 territories examines companies' plans with respect to supply chains, sourcing, capital expenditures,...
How are executives from biopharma companies, CDMOs/CMOs, and suppliers confronting real and potential risks in the wake of new trade policies? A recent DCAT Benchmarking study, conducted prior to COVID-19, examines companies' response to...
Following AbbVie's $63-billion acquisition of Allergan, which closed earlier this month (May 2020), the new AbbVie, reflecting the combined companies, has projected revenues of $50 billion. DCAT Value Chain Insights examines the key products, both...
